BioLineRx Responds to Rumors, Cooling Off Its Share Price

Speculation about its new anti-schizophrenia drug fed 90% spike; company officials state that they have no new information.

comments Print
Responding to speculation about the effectiveness of its experimental anti-schizophrenia drug that nearly doubled the company's share price, officials of BioLineRx announced Sunday they had no information...